6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
Shares of Urban Outfitters, Inc. (NASDAQ:URBN) rose sharply in today's pre-market trading after the company reported better-than-expected financial results for its first quarter on Tuesday. The company reported quarterly earnings of 69 cents per share, which beat the analyst consensus estimate of 52 cents. Quarterly sales clocked in at $1.2 billion, beating the analyst consensus estimate of $1.175 billion, according to data from Benzinga Pro. Urban Outfitters shares jumped 6.7% to $44.10 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MGO Global, Inc. (NASDAQ:MGOL) gained 91.2% to $2.39 in pre-market trading. MGO Global shar
Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeksThe fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to dateThe RESOLVE Phase 1b/2a trial is progressing as anticipated with no serious adverse events reported in all four fully-dosed cohortsVICTORIA, BC, Sept. 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need
VICTORIA, BC, Sept. 4, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting at the upcoming H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Presentation Details: The Company's presentation is at 8:00 a.m. ET on Monday, September 9, 2024. Eupraxia invite
VICTORIA, BC, Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study conti
VICTORIA, BC, Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study conti